Financial Performance - Jiangsu Kangwei Century Biotechnology Co., Ltd. expects a net profit attributable to shareholders of the parent company to range from -111.76 million to -91.44 million yuan, representing a year-on-year reduction in losses of 28.91% to 41.83%[2] - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is expected to be between -143.30 million and -122.98 million yuan, reflecting a year-on-year reduction in losses of 20.64% to 31.90%[2] - The previous year's net profit attributable to shareholders of the parent company was -157.21 million yuan, with a total profit of -164.70 million yuan[3] Business Growth - The main reason for the reduced losses is the significant increase in overall sales revenue, primarily driven by rapid growth in the company's technology service businesses, including gene sequencing and gene synthesis[4] - The company is currently in a recovery phase within the life sciences and diagnostic reagents industry, and new business expansions have not yet achieved economies of scale[4] Forecast and Risks - The earnings forecast is based on preliminary calculations by the company's finance department and has not yet been audited by certified public accountants[5] - Investors are advised to pay attention to investment risks as the forecast data is preliminary and the final financial data will be disclosed in the official 2025 annual report[6]

Core Viewpoint - The company expects a reduction in net loss for the fiscal year 2025, with projections indicating a net profit attributable to the parent company ranging from -111.76 million to -91.44 million, representing a year-on-year decrease in loss of 28.91% to 41.83 [1] Financial Performance - The projected non-GAAP net profit is expected to be between -143.30 million and -122.98 million, showing a year-on-year decrease in loss of 20.64% to 31.90% [1] - The previous year's net profit attributable to the parent company was -157.21 million, and the non-GAAP net profit was -180.57 million [1] Industry Context - The primary reason for the ongoing losses is that the life sciences and diagnostic reagents industry is in a recovery phase, and new business ventures have not yet achieved economies of scale [1] - The reduction in net profit loss is attributed to an increase in main business revenue and rapid growth in technology service operations [1]

在本法律意见书中,本所仅对本次股东会召集和召开的程序、出席本次股东会人员 资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表意见, 并不对本次股东会所审议的议案内容以及该等议案所表述的事实或数据的真实性和准 确性发表意见。 本所及本所律师依据法律法规及本法律意见出具目以前已经发生或者存在的事实, 严格履行了法定职责,遵循了勤勉尽责和诚实信用原则,进行了充分的核查验证,保证 本法律意见所认定的事实真实、准确、完整,所发表的结论性意见合法、准确,不存在 虚假记载、误导性陈述或者重大遗漏,并承担相应法律责任。 在此基础上,本所律师出具法律意见如下: hena Road Mic 上海市通力律师事务所关于江苏康为世纪生物科技股份有限公司 2026 年第一次临时股东会的法律意见书 致:江苏康为世纪生物科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受江苏康为世纪生物科技股份有限 公司(以下简称"公司")的委托,指派本所赵伯晓律师、周奇律师(以下简称"本所 律师")根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会 规则》等法律法规和规范性文件(以下统称"法律法规")及《 ...

证券代码：688426 证券简称：康为世纪 公告编号：2026-006 江苏康为世纪生物科技股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 1 月 28 日 （二） 股东会召开的地点：江苏省泰州市医药高新区泽兰路 18 号江苏康为世纪 生物科技股份有限公司 2 楼会议室 （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 1、本次股东会所采用的表决方式是现场投票和网络投票相结合的方式； 2、本次会议由公司董事会召集，董事长王春香因公务出差以通讯方式接入现场 会议，根据《公司章程》等相关规定，现场会议由半数以上董事共同推举董事庄 志华女士主持。本次会议采用现场投票与网络投票相结合的方式召开。本次会议 的召集、召开程序、表决方式和表决程序均符合《公司法》、《公司章程》及《股 东会议事规则》规定，会议合法有效。 （五） 公司董事和董事会秘书的出席情况 ...

Core Viewpoint - 康为世纪 has shown a significant increase in revenue and a notable change in shareholder structure, indicating potential growth and investment interest in the company. Group 1: Financial Performance - As of January 26, 康为世纪 reported a trading increase of 0.50% with a transaction volume of 32.63 million yuan [1] - For the period from January to September 2025, 康为世纪 achieved an operating income of 140 million yuan, representing a year-on-year growth of 42.01% [2] - The net profit attributable to the parent company for the same period was -76.16 million yuan, reflecting a year-on-year increase of 20.37% [2] Group 2: Shareholder and Financing Information - As of January 26, 康为世纪's financing balance was 78.86 million yuan, accounting for 7.35% of its market capitalization, which is above the 70th percentile of the past year [1] - The number of shareholders as of September 30 was 3,905, a decrease of 1.11% from the previous period, while the average circulating shares per person increased by 1.13% to 9,729 shares [2] - The top circulating shareholder, 融通健康产业灵活配置混合A/B, held 2.60 million shares, a decrease of 1.00 million shares compared to the previous period [3]

Core Viewpoint - The company is currently in the process of calculating its financial data for 2025, indicating ongoing assessments and potential future developments in its financial performance [1] Group 1: Revenue Breakdown - For the fiscal year 2024, the company's foreign revenue is expected to account for approximately 8% of total revenue [1] - Within the foreign revenue, the European Union region is projected to represent about 20%-25% [1] Group 2: Sales Channels - The company utilizes both European cooperative agents for sales and direct collaborations with local chain testing laboratories and hospitals in the EU for distribution [1]

Core Viewpoint - The announcement reveals that three key shareholders of Kangwei Century (688426.SH) plan to reduce their holdings, which will not significantly impact the company's governance or ongoing operations [1][2]. Shareholder Reduction Plans - Shareholder Zhuang Zhihua intends to reduce up to 21,958 shares, representing 0.0195% of the total share capital - Shareholder Qi Yubai plans to reduce up to 11,311 shares, accounting for 0.0101% of the total share capital - Shareholder Yin Jianfeng aims to reduce up to 9,981 shares, which is 0.0089% of the total share capital - The total reduction by these three shareholders will not exceed 43,250 shares, or 0.0385% of the total share capital, with the reduction period set from February 5, 2026, to May 5, 2026 [1][2]. Shareholding Structure - As of the announcement date, Zhuang Zhihua holds 208,930 shares (0.1857% of total share capital), with 121,098 shares held indirectly through a management consulting partnership and 87,832 shares from a 2021 stock incentive plan - Qi Yubai holds 163,872 shares (0.1457% of total share capital), with 118,625 shares held indirectly and 45,247 shares from the 2021 stock incentive plan - Yin Jianfeng holds 116,818 shares (0.1038% of total share capital), with 76,894 shares held indirectly and 39,924 shares from the 2021 stock incentive plan [2]. Company Listing and Financials - Kangwei Century was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 25, 2022, with an issue price of 48.98 yuan per share and a total of 23,290,278 shares issued, of which 25% were publicly offered - The total funds raised amounted to 1,140.7578 million yuan, with a net amount of 1,054.3036 million yuan after deducting issuance costs, exceeding the original fundraising plan by 68.6277 million yuan - The funds are intended for projects related to medical devices, marketing network construction, molecular detection product R&D, and working capital [3][4].

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. announced a share reduction plan involving some directors and senior management due to personal financial needs related to tax obligations from the stock option incentive plan [3][10]. Summary by Sections Shareholding Information - As of the announcement date, key personnel hold the following shares: - Ms. Zhuang Zhihua: 208,930 shares (0.1857% of total shares), with 121,098 shares held indirectly through an employee stock ownership platform [2]. - Mr. Qi Yubai: 163,872 shares (0.1457% of total shares), with 118,625 shares held indirectly [2]. - Mr. Yin Jianfeng: 116,818 shares (0.1038% of total shares), with 76,894 shares held indirectly [2]. Reduction Plan Details - The reduction plan includes: - Ms. Zhuang Zhihua: up to 21,958 shares (0.0195% of total shares) - Mr. Qi Yubai: up to 11,311 shares (0.0101% of total shares) - Mr. Yin Jianfeng: up to 9,981 shares (0.0089% of total shares) - The reduction period is set for three months starting 15 trading days after the announcement [3][6]. Background on Shareholding - The mentioned directors and senior management have not reduced their holdings since the company went public on October 25, 2022 [5]. Compliance and Commitments - The reduction plan aligns with previous commitments made under the 2021 stock option incentive plan, which restricts the transfer of shares for 36 months post-exercise [8][9]. - The company confirms that the reduction does not violate any regulations regarding shareholding reductions [11].

Group 1 - The company 康为世纪 announced a share reduction plan involving three individuals due to personal financial needs and tax obligations related to the 2021 stock option incentive plan [1] -庄志华 plans to reduce up to approximately 22,000 shares, accounting for 0.0195% of the total share capital [1] - 戚玉柏 intends to reduce up to approximately 11,300 shares, representing 0.0101% of the total share capital [1] - 殷剑峰 aims to reduce up to 9,981 shares, which is 0.0089% of the total share capital [1] - The reduction period will commence 15 trading days after the announcement and will last for three months [1] Group 2 - The article mentions 海利生物, which has seen a ninefold increase in valuation through acquisitions, yet its valuation has halved in eight months [1] - The first major client of 海利生物 is a company that has not yet been established, indicating unusual circumstances surrounding its business operations [1]

证券代码：688426 证券简称：康为世纪 公告编号：2026-005 江苏康为世纪生物科技股份有限公司 部分董事、高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 税及其他个人资金需求，庄志华女士拟减持数量不超过 21,958 股，即不超过公 司总股本的 0.0195%；戚玉柏先生拟减持数量不超过 11,311 股，即不超过公司总 股本的 0.0101%；殷剑峰先生拟减持数量不超过 9,981 股，即不超过公司总股本 的 0.0089%。减持期间均为本公告披露之日起 15 个交易日之后的 3 个月内。 如遇派息、送股、转增股本、配股等除权除息事项，上述拟减持股份数量将 相应进行调整，但减持股份占公司总股本的比例不变。 | 股东名称 | 戚玉柏 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | √是 | □ ...